GB0822981D0 - Compounds for treatment of duchenne muscular dystrophy - Google Patents

Compounds for treatment of duchenne muscular dystrophy

Info

Publication number
GB0822981D0
GB0822981D0 GBGB0822981.7A GB0822981A GB0822981D0 GB 0822981 D0 GB0822981 D0 GB 0822981D0 GB 0822981 A GB0822981 A GB 0822981A GB 0822981 D0 GB0822981 D0 GB 0822981D0
Authority
GB
United Kingdom
Prior art keywords
compounds
treatment
muscular dystrophy
duchenne muscular
duchenne
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0822981.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Summit Therapeutics Ltd
Original Assignee
Summit Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Corp PLC filed Critical Summit Corp PLC
Priority to GBGB0822981.7A priority Critical patent/GB0822981D0/en
Publication of GB0822981D0 publication Critical patent/GB0822981D0/en
Priority to PCT/EP2009/065115 priority patent/WO2010069684A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
GBGB0822981.7A 2008-12-17 2008-12-17 Compounds for treatment of duchenne muscular dystrophy Ceased GB0822981D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0822981.7A GB0822981D0 (en) 2008-12-17 2008-12-17 Compounds for treatment of duchenne muscular dystrophy
PCT/EP2009/065115 WO2010069684A1 (en) 2008-12-17 2009-11-13 Compounds for treatment of duchenne muscular dystrophy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0822981.7A GB0822981D0 (en) 2008-12-17 2008-12-17 Compounds for treatment of duchenne muscular dystrophy

Publications (1)

Publication Number Publication Date
GB0822981D0 true GB0822981D0 (en) 2009-01-21

Family

ID=40326239

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0822981.7A Ceased GB0822981D0 (en) 2008-12-17 2008-12-17 Compounds for treatment of duchenne muscular dystrophy

Country Status (2)

Country Link
GB (1) GB0822981D0 (en)
WO (1) WO2010069684A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012004990A (en) 2009-10-30 2012-06-12 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS.
AR080754A1 (en) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv IMIDAZO DERIVATIVES (1,2-A) PIRAZINA AND ITS USE AS PDE10 INHIBITORS
JP5841078B2 (en) * 2010-03-18 2016-01-06 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Imidazopyrazine
ES2555261T3 (en) * 2010-06-01 2015-12-30 Bayer Intellectual Property Gmbh Imidazopyrazines substituted
JP2013545776A (en) * 2010-12-17 2013-12-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 6-substituted imidazopyrazines for use as MPS-1 and TKK inhibitors in the treatment of hyperproliferative disorders
GB201109763D0 (en) * 2011-06-10 2011-07-27 Ucl Business Plc Compounds
AU2012277912B2 (en) 2011-06-27 2017-03-23 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
WO2013016160A1 (en) * 2011-07-26 2013-01-31 Merck Sharp & Dohme Corp. NOVEL IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS mTOR INHIBITORS
AU2013283426B2 (en) 2012-06-26 2018-02-22 Janssen Pharmaceutica Nv Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological or metabolic disorders
CA2875057C (en) 2012-07-09 2021-07-13 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyrazine compounds and their use as inhibitors of the phosphodiesterase 10 enzyme
ES2681593T3 (en) * 2012-11-29 2018-09-14 Chemocentryx, Inc. CXCR7 antagonists
WO2014190250A1 (en) * 2013-05-23 2014-11-27 The Johns Hopkins University Activators of soluable guanylate cyclase and their use in treatment of duchenne muscular dystrophy and related disease
EP3137454A1 (en) 2014-04-28 2017-03-08 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
GB201412010D0 (en) 2014-07-04 2014-08-20 Summit Corp Plc Treatment of hypertransaminasemia
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
AU2016255434C1 (en) 2015-04-29 2021-09-23 Rapport Therapeutics, Inc. Azabenzimidazoles and their use as AMPA receptor modulators
WO2016176457A1 (en) * 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
MA43169B1 (en) 2015-11-06 2022-05-31 Incyte Corp Heterocyclic compounds as pi3k-gamma inhibitors
TW201734003A (en) 2016-01-05 2017-10-01 英塞特公司 Pyridine and pyridimine compounds as PI3K-gamma inhibitors
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
PE20190607A1 (en) 2016-09-02 2019-04-23 Ironwood Pharmaceuticals Inc SGC STIMULATORS
WO2019079469A1 (en) 2017-10-18 2019-04-25 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
DK3847175T3 (en) 2018-09-05 2024-03-18 Incyte Corp CRYSTALLINE FORMS OF A PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR
KR20210102338A (en) 2018-12-12 2021-08-19 케모센트릭스, 인크. CXCR7 inhibitors for the treatment of cancer
WO2021249893A1 (en) * 2020-06-08 2021-12-16 F. Hoffmann-La Roche Ag Novel imidazo-pyrazine derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4242344A (en) * 1979-01-22 1980-12-30 Merck & Co., Inc. Piperazinyl-imidazo[1,2-a]pyrazines
WO2002060492A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US20100144743A1 (en) * 2006-09-05 2010-06-10 Board Of Regents, The University Of Texas System Compositions and methods for inhibition of tyrosine kinases
WO2008029152A2 (en) * 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy

Also Published As

Publication number Publication date
WO2010069684A1 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
GB0815369D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0821307D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0822981D0 (en) Compounds for treatment of duchenne muscular dystrophy
IL228598A0 (en) Treatment of duchenne muscular dystrophy
GB0715938D0 (en) Method of treatment of duchenne muscular dystrophy
PL2170396T3 (en) Drug combinations for the treatment of duchenne muscular dystrophy
GB0715087D0 (en) Drug combinations for the treatment of duchenne muscular dystrophy
IL193314A0 (en) Treatment of duchenne muscular dystrophy
IL229878A (en) Compounds for treatment of cancer
GB0715939D0 (en) Method of treatment of duchenne muscular dystrophy
ZA200806986B (en) Treatment of duchenne muscular dystrophy
IL201908A0 (en) Polymorphs of a compound for the treatment of duchenne muscular dystrophy
EP2576582A4 (en) Treatment of muscular dystrophy
GB0905664D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0905670D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0905667D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0902411D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0901417D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0809314D0 (en) Compounds for treating muscular dystrophy
GB0803906D0 (en) Compounds for treating duchenne muscular dystrophy
GB0807216D0 (en) Drug combination for the treatment of duchenne muscular dystrophy
GB0901794D0 (en) Compounds for treating muscular dystrophy
GB0806130D0 (en) Compounds for treating muscular dystrophy
GB0619281D0 (en) Treatment of duchenne muscular dystrophy
GB0617740D0 (en) Treatment of duchenne muscular dystrophy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)